Survivin、Bcl-2、nm23-H1的表达及其与鼻咽癌病理类型、临床分期的关系  

Expression of Survivin,Bcl-2,nm23-H1 and the relationship with the pathological types and the clinical stage of nasopharyngeal carcinoma(NPC)

作　　者：潘艳东[1] 黎静[1] 尹吉林[1] 陈晓东[1] 李向东[1] 王卓才[1] 李志强[1] 郭晓彤[1] 陈炳旭[1] 张伟[1] 陈敬文[1] 

机构地区：[1]广州军区广州总医院肿瘤科,广东广州510000

出　　处：《现代肿瘤医学》2009年第12期2287-2290,共4页Journal of Modern Oncology

摘　　要：目的:研究Survivin、Bcl-2及nm23-H1的表达及其与鼻咽癌(NPC)病理类型、临床分期之间的关系。方法:应用免疫组化分析32例NPCSurvivin、Bcl-2及nm23-H1的表达。结果:32例NPC组织中Sur-vivin、Bcl-2及nm23-HI的表达率分别为:68.7%(22/32)、71.9%(23/32)、56.3%(18/32);晚期(Ⅲ、Ⅳ期)患者Survivin、Bcl-2阳性表达率分别为90%(18/20)、90%(18/20)明显高于早期(Ⅰ、Ⅱ期)患者的表达率33.3%(4/12)、41.6%(5/12),差异均有显著性(P<0.05);未分化癌患者Survivin、Bcl-2阳性表达率分别为100%(10/10)、100%(10/10)明显高于低分化鳞癌患者表达率54.5%(12/22)、59.1%(13/22),差异均有显著性(P<0.05);有颈部淋巴转移的患者Survivin、Bcl-2阳性表达率分别为69.2%(18/26)、76.9%(20/26)高于无颈部淋巴转移患者表达率66.6%(4/6)、50%(3/6),但均未见显著性(P>0.05);晚期(Ⅲ、Ⅳ期)患者nm23-H的阳性表达率40%(8/20)低于早期(Ⅰ、Ⅱ期)患者的表达水平100%(12/12),差异有显著性(P<0.05),未分化癌患者的阳性表达率(7/10,70%)高于低分化鳞癌患者的表达率54.5%(13/22),但差异无显著性(P>0.05),无颈部淋巴转移患者nm23-H1的阳性表达率100%(6/6)高于有颈部淋巴转移患者表达水平46.1%(12/26),差异有显著性(P<0.05)。结论:鼻咽癌中存在着Survivin、Bcl-2及nm23-H1的高表达;Survivin、Bcl-2与鼻咽癌的临床分期、病理类型具有相关性,而与颈部淋巴转移无相关性,nm23-H1与鼻咽癌的临床分期、颈部淋巴转移具有相关性,但与病理类型无相关性。Objective：To investigate the expression of Survivin, Bcl -2, nm23 - HI and the relationship with the pathological types and the clinical stage of NPC. Methods： To analyze 32 cases of NPC Survivin, Bcl -2 and rim23 -H1 expression with immunohistochemistry. Results ：The positive expression rates of Survivin, Bcl- 2 and nm23 - HI in 32 cases of NPC were 68.7 % （22/32）,71.9% （23/32）, 62.5% （20/32）, respectively. The positive expres- sion rates of Survivin and Bc1-2 in the advanced stage （ Ⅲ,Ⅳ） were higher than the early stage（ Ⅰ,Ⅱ ） with obviously significant difference（P 〈0.05 ） ,respectively. The positive expression rates of Survivin and Bcl -2 in the patients with undifferentiated carcinoma were higher than the poorly differentiated squamous cell carcinoma with obviously significant difference（P 〈0.05）. The positive expression rates of Survivin and Bcl- 2 in the patients with the neck lymph node metastases were higher than no lymph node metastases but no significant difference（P 〉0.05）. The positive expression rates of rim23 - H1 in the advanced stage NPC （ Ⅲ,Ⅳ ） was lower than the early stage（ Ⅰ,Ⅱ ） with obviously significant difference（P 〈0.05）. The positive expression rates of nm23 -H1 in the patients with undifferentiated carcinoma was higher than the poorly differentiated squamous cell carcinoma but with no significant difference（ P 〉 0. 05 ）. The positive expression rate of nm23 -H1 in the patients with the neck lymph node metastases was lower than the no lymph node metastases with obviously significant difference （ P 〈 0. 05 ） . Conclusion： There were high expression of survivin, Bcl - 2, nm23 - H1 in NPC. Survivin and Bcl - 2 expression were related to the dif- ferentiation and the clinical stage of NPC,but were no relevant with the neck lymph node. Nm23 -H1 was related to the neck lymph node and the clinical stage of NPC,but was no relevant with the differentiation.

关 键 词：鼻咽癌 SURVIVIN Bcl一2 nm23一HI 免疫组化 

分 类 号：R739.63[医药卫生—肿瘤]